Patents Examined by Gollamudi S. Kishore
  • Patent number: 10434039
    Abstract: A hygiene tissue includes a composition including one or more lactic acid producing bacterial strains and a lipid phase including at least one lipid, wherein the lipid is selected from the group having olive oil, canola oil, coconut oil, palm kernel oil, peanut oil, soy bean oil, Dimethicone, paraffin oil, and petrolatum; and a matrix impregnated by the composition.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: October 8, 2019
    Assignee: ESSITY HYGIENE AND HEALTH AKTIEBOLAG
    Inventors: Ulla Forsgren Brusk, Bo Runeman, Eva Gran Håkansson
  • Patent number: 10413511
    Abstract: The present invention relates to the preparation of liposomes with enhanced loading capacity for pharmaceutically and/or diagnostically active agents and/or cosmetic agents which are substantially solubilized by the liposomal membranes, to liposome dispersions with enhanced stability with respect to release of the active agent and/or cosmetic agent from the liposomes obtainable by the process, and to pharmaceutical or cosmetic compositions comprising said stabilized liposome dispersions. The preparation may involve dehydration and rehydration steps of liposome dispersions which may be carried out by spray drying.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: September 17, 2019
    Assignee: SynCore Biotechnology Co., Ltd.
    Inventors: Heinrich Haas, Ursula Fattler
  • Patent number: 10406117
    Abstract: The present invention is a water-soluble form of lipophilic molecules contained in liposomes. In one embodiment, the lipophilic molecule is crystalline lutein and the lutein-loaded liposomes are included in pharmaceutical products, medical devices, and dietary supplements industry, with potential for chewable tablets, fortification of beverages, effervescent tablets, uncoated tablets, nutritional bars, and functional foods in addition to cosmetic industry.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: September 10, 2019
    Assignee: KEMIN INDUSTRIES, INC.
    Inventor: Diogo de Sousa Martins
  • Patent number: 10398801
    Abstract: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. The subject phase invertible compositions are prepared by combining a proteinaceous substrate and a crosslinking agent, such as a stabilized aldehyde crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: September 3, 2019
    Assignee: BAXTER INTERNATIONAL INC.
    Inventors: Kemal Schankereli, Ronald Dieck
  • Patent number: 10383823
    Abstract: The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-65 mol % of a phosphatidylcholine lipid, 30-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and cisplatin. Cisplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the cisplatin weight is from about 65:1 to about 95:1. Methods for the preparation of liposomal cisplatin and the treatment of cancer are also disclosed.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: August 20, 2019
    Assignee: MALLINCKRODT LLC
    Inventor: William McGhee
  • Patent number: 10357448
    Abstract: We disclose a composition comprising an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and a thrombolytic compound trapped by the ELIP. We also disclose a method of treating a medical condition in a patient characterized by a thrombus in the patient's vasculature, comprising administering to the patient the composition in an amount effective to reduce the size of the thrombus.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: July 23, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Susan T. Laing, Shaoling Huang, David D. McPherson, Christy K. Holland, Melvin E. Klegerman
  • Patent number: 10300017
    Abstract: A medicament for treating cystitis and a method of treatment are provided. An agent to repair the damaged glycosaminoglycan (“GAG”) layers lining the urothelium, noted in cystitis, such as pentosan polysulfate, hyaluronic acid, chondroitin, etc., is provided in a liposomal carrier. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 28, 2019
    Assignee: Nanologix Research, Inc.
    Inventors: Elliot B. Lander, Jackie R. See
  • Patent number: 9421238
    Abstract: The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: August 23, 2016
    Assignees: YOUR ENERGY SYSTEMS, LLC, EMORY UNIVERSITY, CHILDREN'S HALTHCARE OF ATLANTA, INC.
    Inventors: Lou Ann Brown, Frederick Timothy Guilford
  • Patent number: 9271492
    Abstract: The present invention relates to an antimicrobial composition and a method for disinfection involving the antimicrobial composition. It particularly relates to an antimicrobial composition for personal cleaning, oral care or hard surface cleaning applications. It was found that compositions comprising thymol, menthadiene alcohols and a carrier provide synergistic antimicrobial action. In a preferred aspect the composition also comprises 1 to 80%-wt of one or more surfactants.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: March 1, 2016
    Assignee: Dow Global Technologies LLC
    Inventors: Robert J. Cornmell, Megan A. Diehl, Stephen Golding, John R. Harp, Ian P. Stott, Katherine M. Thompson, Carol L. Truslow
  • Patent number: 7968115
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: June 28, 2011
    Assignee: Board of Regents, The University of Texas System
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal
  • Patent number: 7943119
    Abstract: Provided are a leave-on hair cosmetic composition, containing the following components (A), (B) and (C): (A) an organic dicarboxylic acid or salt thereof, (B) an organic solvent selected from aromatic alcohols, N-alkylpyrrolidones, alkylene carbonates, polypropylene glycols having a number average molecular weight of from 100 to 1000, lactones and cyclic ketones, and (C) an organopolysiloxane having an organopolysiloxane segment and a poly(N-acylalkyleneimine) segment having a recurring unit represented by the following formula (1): (wherein, R1: H, C1-22 alkyl, cycloalkyl, aralkyl or aryl, and n: 2 or 3), wherein the latter segment has been bonded to at least one silicon atom of the former segment via a hetero-atom-containing alkylene group; having the organopolysiloxane segment and the poly(N-acylalkyleneimine)segment at a weight ratio of from 98/2 to 40/60; and having a weight average molecular weight of from 50,000 to 500,000; and a hair treating method with the composition.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: May 17, 2011
    Assignee: Kao Corporation
    Inventors: Michiko Tada, Keiko Ishii, Shiyo Shichiri, Tamami Iwase
  • Patent number: 7939106
    Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: May 10, 2011
    Assignee: Jagotec AG
    Inventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
  • Patent number: 7939105
    Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: May 10, 2011
    Assignee: Jagotec AG
    Inventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
  • Patent number: 7935680
    Abstract: Methods for modulating the axonal outgrowth of central nervous system neurons are provided. Methods for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, Traumatic Brain Injury, cerebral aneurism, spinal cord injury and the like) and methods for inhibiting the axonal outgrowth of central nervous system neurons are also provided. Finally, a packed formulation comprising a pharmaceutical composition comprising an inosine nucleoside and a pharmaceutically acceptable carrier packed with instructions for use of the pharmaceutical composition for treatment of a central nervous system disorder is provided.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: May 3, 2011
    Assignee: Children's Medical Center Corporation
    Inventor: Larry Benowitz
  • Patent number: 7906139
    Abstract: Compositions comprising lamellar bodies for removal of extra and intra-vascular fibrin for therapeutic purposes are disclosed. These lamellar compositions are also useful in surgical procedures wherein formation of post-surgical adhesions are likely. Methods of preventing and/or modifying fibrin clots and treating and/or preventing adhesions by administering a therapeutically effective amount of a composition to a patient requiring such treatment are also disclosed.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: March 15, 2011
    Assignee: Lamellar Therapeutics Limited
    Inventor: James Dobbie
  • Patent number: 7906554
    Abstract: This invention relates to combination therapies involving anticancer chemotherapeutic agents and isoflavones or analogues thereof. The invention further relates to compounds, methods and therapeutic uses involving, containing, comprising, including and/or for preparing platinum-isoflavonoid complexes suitable for use in the combination therapies of the invention.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: March 15, 2011
    Assignee: Novogen Research Pty Ltd
    Inventor: Graham Edmund Kelly
  • Patent number: 7901707
    Abstract: Formulations or delivery systems are provided for controlled release of therapeutically active agents. The delivery systems are composed of polymer and lipid materials and may be prepared as a gel, paste, solution, film, implant or barrier depending on the intended application. The polymer component of the matrix is the naturally occurring biomaterial, chitosan, or a mixture of chitin and chitosan. The lipid component may include phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidyl or a mixture thereof. The delivery system may be used for delivery of hydrophilic agents, hydrophobic agents or combinations thereof. The therapeutically active agents may be formulated within the matrix as free agents or incorporated into particles. In a preferred embodiment the agents are incorporated into polymeric particles that are dispersed throughout the matrix.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: March 8, 2011
    Inventors: Christine Allen, Justin Grant, Micheline Piquette-Miller
  • Patent number: 7901706
    Abstract: The present invention provides a composite material, preferably an ophthalmic device, more preferably a contact lens, which comprises a vesicle-containing coating including at least one layer of a vesicle and one layer of a polyionic material having charges opposite the charges of the vesicle. Such composite material can find use in biomedical applications, for example, a device for localized drug delivery and an in vivo analyte sensor such as glucose sensing contact lens. By lifting off the vesicle-containing coating from a substrate, a self-standing membrane (film) capable of encapsulating a wide variety of guest materials can be prepared. In addition, the invention provides methods for making vesicle-containing composite and film materials of the present invention.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: March 8, 2011
    Assignee: Novartis AG
    Inventors: John Martin Lally, Nicholas Kotov
  • Patent number: 7901709
    Abstract: A liposome contains an active agent and has a gel-phase lipid bilayer membrane comprising phospholipid and a surface active agent. The phospholipids are the primary lipid source for the lipid bilayer membrane and the surface active agent is contained in the bilayer membrane in an amount sufficient to increase the percentage of active agent released at the phase transition temperature of the lipid bilayer, compared to that which would occur in the absence of the surface active agent. The surface active agent is present in the lipid bilayer membrane so as to not destabilize the membrane in the gel phase.
    Type: Grant
    Filed: April 12, 2005
    Date of Patent: March 8, 2011
    Assignee: Duke University
    Inventor: David Needham
  • Patent number: 7887836
    Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: February 15, 2011
    Assignees: Hana Biosciences, Inc., Board of Regents, The University of Texas System
    Inventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb